The blood test offers critical support to men aged between 40 and 45. Credit: National Cancer Institute on Unsplash.

Diagnostic test provider Nanostics has initiated a new blood test for prostate cancer screening in Alberta, Canada.

The ClarityDX Prostate test is available at the company’s clinical lab in Edmonton.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Developed to offer critical support to men aged between 40 and 45, the test will enable physicians to make informed decisions with greater accuracy.

It will help confirm the use of a biopsy after a high prostate-specific antigen test result.

Nanostics CEO Dr John Lewis said: “This test will reduce the number of unnecessary prostate biopsies, which are invasive, uncomfortable and carry some risk.”

Research demonstrated that the addition of ClarityDX Prostate to the patient care pathway could lower unnecessary prostate biopsies by up to 35%, thereby significantly reducing costs.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The Alberta Prostate Cancer Research Initiative, the University of Alberta and global research institutions have supported the company in developing and validating this test.

ClarityDX is the company’s core technology that leverages machine learning algorithms to create a disease risk score. It can be used for a wide range of cancers and other diseases.

Alberta Cancer Foundation CEO Wendy Beauchesne said: “We are dedicated to creating more moments for Albertans facing cancer and it’s a mission we share with Dr Lewis and the Nanostics team.

“Through the launch of ClarityDX Prostate, we are enhancing detection and treatment options. It’s incredible to see what can happen when Albertans come together to support big ideas.”